AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7814081
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel 0.5 mg
Trial: 19288084
Drug: Ketanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20 mg)
Trial: 3768242
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg) plus Ketanserin (20 mg)
Trial: 29581212
Drug: 8-week Alert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week Alert Program school curriculum delivered in weekly 1-hour lessons by trained classroom teachers.
Trial: 21628604
Drug: Asenapine 5
RxNorm normalized name: asenapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 5 mg alone
Trial: 21628604
Drug: Asenapine 5
RxNorm normalized name: asenapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 5 mg under steady‐state valproate (500 mg bid for 9 days)
Trial: 20642579
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) with depigmented polymerized birch pollen extract
Trial: 26743539
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of purified Plasmodium falciparum sporozoites (n = 24)
Trial: 26743539
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of purified Plasmodium falciparum sporozoites (n = 6)
Trial: 19149819
Drug: AIDSVAX B/E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIDSVAX B/E HIV vaccine
Trial: 17495764
Drug: Oral alpha-lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alpha-lipoic acid (ALA) 600 mg
Trial: 17495764
Drug: Oral alpha-lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alpha-lipoic acid (ALA) 1200 mg
Trial: 17495764
Drug: Oral alpha-lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral alpha-lipoic acid (ALA) 1800 mg
Trial: 9870877
Drug: cA2 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cA2 at 5, 10, or 20 mg/kg
Trial: 28707217
Drug: 1% milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% milk (12 g carbohydrates)
Trial: 28707217
Drug: apple juice
RxNorm normalized name: apple juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apple juice (29 g carbohydrates)
Trial: 27011386
Drug: Lumbrokinase DLBS1033
RxNorm normalized name: LUMBROKINASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbrokinase DLBS1033 490 mg 3 times daily
Trial: 18816008
Drug: Emotion-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotion-focused therapy
Trial: 10901907
Drug: Accelerated (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated (twice daily) radiotherapy
Trial: 8196726
Drug: Cyclosporine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (4 mg per kilogram of body weight per day)
Trial: 23866823
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg benralizumab (single-dose intravenous)
Trial: 23866823
Drug: 100 or
RxNorm normalized name: Stalevo 100 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 or 200 mg benralizumab (3 monthly subcutaneous doses)
Trial: 15304046
Drug: Heparin (9000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (9000 IU of four heparins of different mol. wt distributions)
Trial: 11402638
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 8 mg + Oral Contraceptive (OC)
Trial: 11402638
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo (P) + Oral Contraceptive (OC)
Trial: 7904085
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with disease-modifying antirheumatic drugs (DMARDs), specific details on dosage and duration not available.
Trial: 25772594
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol therapy
Trial: 16920898
Drug: Amlodipine besylate/atorvastatin
RxNorm normalized name: Amlodipine Besylate/Atorvastatin Calcium 5 MG-80 MG Oral Tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate/atorvastatin calcium combination tablet (10/80 mg; n = 62)
Trial: 16920898
Drug: Amlodipine besylate/atorvastatin
RxNorm normalized name: Amlodipine Besylate/Atorvastatin Calcium 5 MG-80 MG Oral Tablet
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate/atorvastatin calcium combination tablet (5/10 mg; n = 64)
Trial: 15494466
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (HT; conjugated estrogens, 0.625 mg/d; trimonthly medroxyprogesterone acetate, 5 mg/d for 13 d)
Trial: 9155120
Drug: Gelseal (g-G0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelseal (g-G0, n = 7)
Trial: 9155120
Drug: Hemashield (g-H0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemashield (g-H0, n = 8)
Trial: 9155120
Drug: Hemashield (g-H,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemashield (g-H, n = 7)
Trial: 9155120
Drug: Gelseal (g-G,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelseal (g-G, n = 5)
Trial: 9155120
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (g-G and g-H)
Trial: 9155120
Drug: Gelseal (g-G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelseal (g-G)
Trial: 9155120
Drug: Hemashield (g-H)
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hemashield (g-H)
Trial: 8399497
Drug: 0.5% podophyllotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% podophyllotoxin lotion
Trial: 8399497
Drug: 25% podophyllin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% podophyllin solution
Trial: 3527643
Drug: Horse-chestnut seed
RxNorm normalized name: horse chestnut seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse-chestnut seed extract (Venostasin retard) 600 mg (two capsules of 50 mg aescin each)
Trial: 3527643
Drug: Placebo (identical-looking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical-looking capsule)
Trial: 22018188
Drug: Prednisone 3
RxNorm normalized name: prednisone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 3 mg/day
Trial: 19360864
Drug: Facilitated PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated PCI with low-dose tenecteplase (10 mg)
Trial: 19360864
Drug: Facilitated PCI
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facilitated PCI with low-dose tenecteplase
Trial: 16297507
Drug: Vaccinated patients
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated patients without systemic steroids for the previous 3 months, treated with steroids for 4 weeks
Trial: 16297507
Drug: Vaccinated patients
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated patients with chronic steroid treatment both before and during the investigation
Trial: 16297507
Drug: Vaccinated patients
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinated patients without systemic steroids for the previous 3 months, vaccinated after 4 weeks of steroid treatment
Trial: 11140430
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 1000 microg by inhalation via Diskhaler
Trial: 11140430
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 1000 microg by inhalation via Diskus
Trial: 11140430
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 1000 microg twice daily via Diskhaler
Trial: 3652469
Drug: Progesterone (50‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (50‐100 mg/d for 7 d)
Trial: 3652469
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg/h for 8 h) after progesterone treatment
Trial: 31978434
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate 50 mg orally 8 hourly up to 150 mg
Trial: 27591784
Drug: Ophthalmic artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic artery (OA) blood flow measurement using ultrasound color doppler imaging (CDI)
Trial: 26971823
Drug: Topical ethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ethyl chloride
Trial: 26971823
Drug: Placebo (sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sterile water aerosol spray)
Trial: 24387624
Drug: 60-minute loading
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-minute loading infusion of magnesium sulphate (4 g over 60 minutes)
Trial: 24387624
Drug: 20-minute loading
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-minute loading infusion of magnesium sulphate (4 g over 20 minutes)
Trial: 24387624
Drug: 60-minute loading
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-minute loading infusion of magnesium sulphate
Trial: 24387624
Drug: 20-minute loading
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-minute loading infusion of magnesium sulphate
Trial: 21717444
Drug: Cenersen inhibitors
RxNorm normalized name: Cenersen
DrugBank: Cenersen (DB15455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenersen inhibitors (acetaminophen and/or high dose antioxidants)
Trial: 19608835
Drug: Extended perineural
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended perineural ropivacaine infusion (n = 24)
Trial: 17499389
Drug: Alcohol-based spray
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol-based spray sunscreen
Trial: 11864853
Drug: n-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 polyunsaturated fat diet (sunflower oil + 4-4.5 g fish oil/d)
Trial: 11332869
Drug: alpha‐dihydroergocryptine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐dihydroergocryptine (10 mg twice daily)
Trial: 11279920
Drug: flunarizine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flunarizine (5 mg once daily)
Trial: 7778155
Drug: Aminosidine 12
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine 12 mg/kg/d with sodium stibogluconate 20 mg/kg/d
Trial: 7778155
Drug: Aminosidine 12
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine 12 mg/kg/d with sodium stibogluconate 10 mg/kg/d
Trial: 7778155
Drug: Aminosidine 12
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine 12 mg/kg/d with sodium stibogluconate 5 mg/kg/d
Trial: 7778155
Drug: Aminosidine 6
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine 6 mg/kg/d with sodium stibogluconate 20 mg/kg/d
Trial: 7778155
Drug: Aminosidine 6
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine 6 mg/kg/d with sodium stibogluconate 10 mg/kg/d
Trial: 7778155
Drug: Aminosidine 6
RxNorm normalized name: Aminosidine
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminosidine 6 mg/kg/d with sodium stibogluconate 5 mg/kg/d
Trial: 7778155
Drug: Overall success
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall success rate with aminosidine 12 mg/kg/d
Trial: 7778155
Drug: Overall success
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall success rate with aminosidine 6 mg/kg/d
Trial: 7778155
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of aminosidine 12 mg/kg/d vs 6 mg/kg/d
Trial: 6162348
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream applied under occlusive dressing for 60 minutes
Trial: 29234808
Drug: Levothyroxine (25-μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (25-μg/d or 50-μg/d, titrated according to TSH levels during pregnancy)
Trial: 29234808
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no levothyroxine treatment)
Trial: 26251480
Drug: Monthly health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly health education meetings and monthly calls from the study coordinator
Trial: 14742609
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of quetiapine
Trial: 14742609
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day of quetiapine (open label phase)
Trial: 11851736
Drug: Lower leg
RxNorm normalized name: CAPSAICIN 0.18 g in 100 g TOPICAL CLOTH [Nufabrx Lower Leg Sleeve]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower leg casting prior to BTX‐A injections
Trial: 11851736
Drug: Casting immediately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casting immediately after BTX‐A injections
Trial: 9870539
Drug: Implant prostheses
RxNorm normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant prostheses
Trial: 2680476
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (plateau insulin concentration 50‐55 mU/l)
Trial: 21884956
Drug: Ingesting all
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingesting all prescribed hypertension medications upon awakening
Trial: 22158066
Drug: Ingesting ≥1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingesting ≥1 hypertension medication at bedtime
Trial: 22152013
Drug: High-dose erythropoiesis-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose erythropoiesis-stimulating agents (ESA) (≥ 1 μg/kg/week)
Trial: 22152013
Drug: Usual-dose erythropoiesis-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-dose erythropoiesis-stimulating agents (ESA) (< 1 μg/kg/week)
Trial: 22152013
Drug: Higher ESA
RxNorm normalized name: esafoxolaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher ESA dose (per μcg/kg/week)
Trial: 22152013
Drug: High-dose erythropoiesis-stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose erythropoiesis-stimulating agents (ESA)
Trial: 15156393
Drug: Bupivacaine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 80 mg in 25 cc of saline
Trial: 11305844
Drug: Generic clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic clozapine (Zenith Goldline Pharmaceuticals)
Trial: 11305844
Drug: Clozaril (Novartis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozaril (Novartis Pharmaceuticals)
Trial: 9438889
Drug: Gravity flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gravity flow administration of local anesthetic (Group 1)
Trial: 9438889
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection (Group 2)
Trial: 7705775
Drug: Bezafibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (200 mg three times daily for 4 weeks)
Trial: 2650694
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with fish oil providing about 3.2 g n-3 fatty acids per day
Trial: 31867715
Drug: Carbetocin (ED90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (ED90 estimated as 62.9 μg using truncated Dixon and Mood method)
Trial: 31867715
Drug: Carbetocin (ED90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (ED90 estimated as 68 μg using isotonic regression method)
Trial: 31141159
Drug: Oral glibenclamide
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glibenclamide (GBC)
Trial: 23875809
Drug: Vitamin D-fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D-fortified doogh (DD; containing 150 mg calcium and 500 IU vitamin D/250 mL)
Trial: 23875809
Drug: Calcium- and
RxNorm normalized name: Calcium- and magnesium-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium- and vitamin D-fortified doogh (CDD; containing 250 mg calcium and 500 IU vitamin D/250 mL)
Trial: 23875809
Drug: Plain doogh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain doogh (PD; containing 150 mg calcium and no detectable vitamin D/250 mL)
Trial: 19797554
Drug: Desensitizing gel
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desensitizing gel (5 percent nitrate potassium/2 percent sodium fluoride) applied before in-office bleaching
Trial: 19797554
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied before in-office bleaching
Trial: 19797554
Drug: Desensitizing gel
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desensitizing gel (5 percent nitrate potassium/2 percent sodium fluoride)
Trial: 16895889
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (daily capsule containing 120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 µg Se, and 20 mg Zn)
Trial: 11712091
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg primaquine daily for 20 weeks
Trial: 8703810
Drug: Tucaresol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tucaresol (oral doses; loading dose of 800 mg or 1200 mg for the first 4 days, followed by maintenance doses of 200 mg or 300 mg for the next 6 days; subsequent cohorts received 300 mg daily)
Trial: 28253863
Drug: Dexmedetomidine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.4 μg/kg/h after a loading dose of 1.0 μg/kg for 10 min)
Trial: 28253863
Drug: Propofol (1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.6 μg/ml target effect site concentration)
Trial: 26844873
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide LAR (40 mg, n = 14)
Trial: 24954822
Drug: Supportive Nondirective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Nondirective Therapy (SNDT)
Trial: 15726912
Drug: Menotropins plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menotropins plus mini-dose GnRH-analog (600 microg/day) (group B)
Trial: 15726912
Drug: Menotropins plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menotropins plus standard dose GnRH-analog (900 microg/day) (group C)
Trial: 7631946
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (LR) alone
Trial: 7631946
Drug: Glucose-free infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-free infusion (LR group)
Trial: 7631946
Drug: 2% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% glucose in lactated Ringer's solution (D2LR) and 5% glucose in lactated Ringer's solution (D5LR)
Trial: 7631946
Drug: Glucose-free solution
RxNorm normalized name: glucose Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-free solution (LR group)
Trial: 28590244
Drug: Tralokinumab 300
RxNorm normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab 300 mg administered as two 1‐mL subcutaneous injections every 2 weeks
Trial: 28590244
Drug: Tralokinumab 300
RxNorm normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab 300 mg administered as one 2‐mL injection delivered over different rates (10 seconds, 1 minute, 12 minutes)
Trial: 28590244
Drug: Tralokinumab 300
RxNorm normalized name: TRALOKINUMAB 300 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Adbry]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tralokinumab 300 mg administered by different injection rates
Trial: 19432292
Drug: Drug acquisition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug acquisition